Actively Recruiting
Study to Assess Safety, Pharmacokinetics, and Early Effects of AMX-883 Alone and with Posaconazole in Adults with AML and High-Risk MDS
Led by Amphista Therapeutics Ltd · Updated on 2026-11-02
54
Participants Needed
3
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating AMX-883, a drug being studied for safety, how it moves through the body, and early effectiveness in adults with acute myeloid leukaemia AML and high-risk myelodysplastic syndrome MDS. This phase 1, open-label study includes participants with relapsed or refractory AML and high-risk MDS to find the best dose and gather preliminary results that may support further development. The study has a module that tests AMX-883 alone and in combination with posaconazole, another anticancer agent. Participants receive oral doses of AMX-883 in escalating amounts either by itself or alongside posaconazole. The module includes parts for dose escalation, evaluating the effect of food on AMX-883 absorption, and combining AMX-883 with posaconazole. Additional modules may be added later. Participants will be closely monitored during and after treatment cycles, which last 28 days each. Researchers will track safety by recording adverse events and dose-limiting toxicities. They will also measure how AMX-883 is processed in the body through blood tests over nearly three years. Effectiveness will be assessed through remission rates, survival outcomes, and changes in specific blood markers. This monitoring helps ensure careful evaluation of the drugs impact and participant safety throughout the study.
CONDITIONS
Brief Title
Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML
Research Team
A
Amphista Medical Monitor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here